Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 25, 2005 Stephen D. Simpson	Prognosis Good for Merck The pharmaceutical weathered a tough year but should ride out its Vioxx troubles. While strict value investors may be put off, risk-tolerant investors can buy these shares today.
The Motley Fool January 31, 2007 Brian Lawler	Merck Plays the Waiting Game New acquisitions may help the drugmaker weather tough times. Investors, take note.
Chemistry World April 2, 2007	European Generics Suppliers Hit Generics drug manufacturers have lost a slice of their market with the reinstatement of a European patent covering Merck's multi-billion-dollar osteoporosis drug, Fosamax.
The Motley Fool August 22, 2005 Stephen D. Simpson	Vioxx Brings the Pain A jury stings Merck for hefty Vioxx damages, battering shares.
The Motley Fool December 21, 2006 Brian Lawler	Dueling Fools: Merck Bull What you are getting with Merck is one of the best-managed pharmas out there that will be experiencing solid double-digit earnings growth in the not-too-distant future with a smart dividend payout.
The Motley Fool December 21, 2006 Brian Lawler	Dueling Fools: Merck Bull Rebuttal Plenty of cash. Big pipeline. Not to worry. The future can't be predicted, but Merck's history shows its ability to weather even the toughest pharmaceutical-development environments.
The Motley Fool October 22, 2008 Brian Orelli	Merck's a Bloated Garbage Heap of Stale Drugs Now Merck is planning on cutting 12% of its workforce in the hopes of saving $4 billion through 2013.
The Motley Fool June 23, 2005 Rich Smith	Dueling Fools: Merck Bull Rebuttal Priced at a P/E of 13 and paying you a 4.8% dividend, Merck isn't just affordable -- it's a stock you can't afford not to own.
The Motley Fool May 12, 2010 Brian Orelli	Is Merck a Buy? Short term it's hard to say, but for the long term, its pipeline looks strong.
The Motley Fool September 25, 2006 Brian Lawler	Merck's Positive Contribution Bad press from Vioxx shouldn't overshadow the company's new offering. Investors, take note.
BusinessWeek July 25, 2005 Gene G. Marcial	Is Merck Rallying After That Nasty Tumble? Although most analysts who track Merck remain bearish on the beleaguered drugmaker, some upbeat investors are buying. Why? It's Vioxx market may have softened, but its new vaccines will rise to the occasion.
The Motley Fool January 31, 2008 Brian Orelli	One Last Look at Pre-Enhance Merck Investors show they care more about Merck's future than its Q4 results.
The Motley Fool October 23, 2006 Brian Lawler	Merck Mints Money The pharmaceutical hangs on, despite ongoing Vioxx woes. Conservative investors may do best to stay away from Merck until a lower share-price opportunity presents itself, now that shares are no longer sporting such a large Vioxx discount.
The Motley Fool June 23, 2005 Rich Smith	Dueling Fools: Merck Bull It's hard to argue with a price this cheap. With a price-to-free cash flow ratio of less than 11, Merck's a steal.
The Motley Fool September 30, 2004 W. D. Crotty	Merck Chokes Back Vioxx The $2.3 billion arthritis drug is withdrawn from the market after clinical studies point to dangerous side-effects. Despite the bad news, Merck's big dividend payouts don't appear to be in jeopardy at the moment.
The Motley Fool June 23, 2005 Stephen D. Simpson	Dueling Fools: Merck Bear Looking at other big pharma peers, Merck is dead last when it comes to expected three- to five-year EPS growth. Why buy a troubled pharma when better options exist?
The Motley Fool March 2, 2005 Brant David McLaughlin	Merck's Road to Recovery Merck didn't get to where it is by being shortsighted, and management has no plans to start now. Investors would be wise not to take on an excessively negative attitude toward the company in the wake of some dark news.
The Motley Fool January 10, 2012 Sean Williams	2012 Preview: Merck The biggest question mark facing the pharmaceutical behemoth in 2012 is just how badly it will be affected by losing patent-exclusivity rights on its biggest drug, Singulair.
The Motley Fool October 21, 2004 Brian Gorman	Merck Is Down But Not Out The pharma's woes may have silver linings. For now, the company's investors might want to sit tight.
The Motley Fool December 21, 2006 Ryan Fuhrmann	Dueling Fools: Merck Bear Investors, because of its recent run-up, the risk/reward tradeoff is not very compelling. There are safer, more lucrative ways to invest in the space.
The Motley Fool December 5, 2007 Brian Orelli	Merck Stays Conservative Merck sets the bar low with its 2008 guidance. Is the company being overly cautious?
The Motley Fool April 17, 2007 Brian Lawler	Merck Raises the Earnings Roof Shares of Merck soar after it raises 2007 earnings guidance.
The Motley Fool September 7, 2007 Billy Fisher	Epic Vioxx Victory for Merck Merck scores a major victory in its Vioxx saga in the courtroom as New Jersey's Supreme Court rules against the possibility of a national class action Vioxx lawsuit. Shares react positively.
The Motley Fool December 29, 2006 Brian Lawler	Sirna Decides to Take the Cash and Run Shareholders vote to approve Merck's buyout offer. Investors in shares of Merck really have to trust management to have done its due diligence on Sirna and to have faith in its technology.
The Motley Fool April 21, 2009 Brian Orelli	Schering and Merck: A Match Made in Purgatory Until Merck can show that it's capable of growing sales again, investors should be leery of stepping in, even with the dividend yield pushing 6%.
The Motley Fool October 4, 2004 Mathew Emmert	Got Merck? The pharmaceutical's investors can't seem to catch a break.
The Motley Fool July 18, 2008 Brian Orelli	Foolish Forecast: How Quickly Can Merck Turn It Around? Views you can use to get clues on the news.
BusinessWeek September 5, 2005 Amy Barrett	The Pain Is Just Beginning Why the Vioxx debacle will hobble Merck for years to come
The Motley Fool November 12, 2004 Chuck Saletta	Three Magical Words Margin of safety are the three most important words in value investing.
The Motley Fool February 28, 2007 Brian Lawler	Merck's Mighty Future Merck ups its 2007 financial forecast, while positive developments occur for two of its most promising new therapies.
The Motley Fool November 25, 2011 Dan Caplinger	Has Merck Become the Perfect Stock? Like most other pharma companies, Merck is dealing with the imminent loss of patent protection on one of its blockbuster drugs.
The Motley Fool April 21, 2005 Stephen D. Simpson	Merck Looks for Soft Landing Despite a tough year, the business isn't falling apart, and the pipeline has some near-term gems. This should give investors reason to expect that better things could be on the way.
The Motley Fool July 8, 2010 Brian Orelli	Surprise Us in a Good Way, Merck Keeping up productivity during plant closures won't be easy.
The Motley Fool April 22, 2008 Brian Orelli	Will Merck Make It? Merck releases first-quarter results and says it can meet its previous guidance.
The Motley Fool July 30, 2010 Brian Orelli	It's Hard to Get Excited About 92% Revenue Growth Especially when revenue dropped on a comparable basis.
The Motley Fool August 26, 2005 Stephen D. Simpson	Merck Broaches the Obvious Merck will naturally end up settling many Vioxx cases, but the details are far from clear at this point. Investors, take note.
The Motley Fool October 24, 2005 Stephen D. Simpson	Merck Needs to Take Its Medicine It will be a long, long time before business at the pharmaceutical returns to business as usual. Turnarounds can pay off for patient investors.
Bio-IT World December 15, 2004 Kevin Davies	Patients Before Profits? After the Vioxx disaster, Pharma needs to reassure patients that they come first.
The Motley Fool September 18, 2007 Brian Orelli	New York Tag-Teams Merck Both the city and state of New York sue Merck over Vioxx payments, alleging the big pharma defrauded Medicaid and other government agencies, by hiding problems related to its painkilling drug.
The Motley Fool July 21, 2005 Stephen D. Simpson	Merck Is No Quack Weighing the pros and cons, it appears that Merck's stock is trading pretty much where it should be. What does make the story a bit more interesting is that robust dividend, which is currently yielding almost 4.8%.
The Motley Fool November 15, 2004 Mathew Emmert	Merck's Silver Lining The government joins the plethora of lawsuit filers, but Merck will survive. Still, the stock remains appropriate for only those investors with a high tolerance for risk and a long-term time horizon.
The Motley Fool February 23, 2005 Stephen D. Simpson	Take Two on COX-2 FDA panel recommendations breathe new life into Merck and Pfizer's COX-2 pain medications. Looking ahead, investors should give a good, long look to the drug sector.
The Motley Fool September 11, 2008 Brian Orelli	Vive le Vioxx Lawsuit Just when Merck thought it was finally done with lawsuits pertaining to Vioxx, it's gotten pulled back in.
The Motley Fool December 21, 2006 Ryan Fuhrmann	Dueling Fools: Merck Bear Rebuttal Yes, Merck is a good company, but investors can still do better.
The Motley Fool March 9, 2009 Brian Orelli	Merck-Schering Trumps Pfizer-Wyeth The new Merck deal looks a lot better than a combined Pfizer plus Wyeth.
The Motley Fool January 25, 2006 Tim Hanson	Find the Silver Lining Falling stock prices don't have to be all bad news. While market drops can test your will, it's always best to keep a level head.
The Motley Fool April 3, 2006 Rich Duprey	Merck Outclassed Class action status is granted to third parties -- like health insurance companies, HMOs, and unions -- in a Vioxx lawsuit. Investors, this is a disturbing development.
The Motley Fool January 14, 2011 Brian Orelli	Don't Have a Stroke Over Merck's Heart Drug Welcome to pharma investing.
The Motley Fool April 11, 2007 Billy Fisher	A Replacement for Vioxx at Merck? Drug company has new pain medication in the pipeline. If Arcoxia is approved despite the long odds against it, it could payoff over the long run for Merck shareholders.
The Motley Fool October 23, 2007 Brian Orelli	Old Merck on New Drugs It looks like the old Merck is back, with new drugs driving double-digit sales growth in the third-quarter.